Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study (vol 24, 229, 2023)

被引：0

作者：

Ismaila, Afisi S. ^{[1
,2
]}

Rothnie, Kieran J. ^{[3
]}

Wood, Robert P. ^{[4
]}

Banks, Victoria L. ^{[4
,5
]}

Camidge, Lucinda J. ^{[4
]}

Czira, Alexandrosz ^{[3
]}

Compton, Chris ^{[6
]}

Sharma, Raj ^{[6
]}

Millard, Shannon N. ^{[4
,7
]}

Massey, Olivia ^{[4
]}

Halpin, David M. G. ^{[8
]}

机构：

[1] GSK, R&D Global Med, Value Evidence & Outcomes, 1250 South Collegeville Rd, Collegeville, PA 19426 USA

[2] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada

[3] GSK, Value Evidence & Outcomes, R&D Global Med, London, England

[4] Adelphi Real World, Real World Evidence, Bollington, England

[5] Bayer PLC, Integrated Evidence Generat Womens Hlth Care, Reading, England

[6] GSK, Global Med, London, England

[7] P1vital Ltd, Wallingford, Oxon, England

[8] Univ Exeter, Med Sch, Coll Med & Hlth, Exeter, England

来源：

关键词：

D O I：

10.1186/s12931-024-02745-x

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：2

共 22 条